Sandoz appeals to US Supreme Court over ‘patent dance’ ruling
17-02-2016
Sandoz launches Zarxio biosimilar
04-09-2015
jiris / Shutterstock.com
The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal; Sandoz; Amgen; Novartis; biosimilars; patent dance; Zarxio; Neupogen; Biologics Price Competition and Innovation Act;
